Correction
This article was originally published in The Tan Sheet
Executive Summary
In the article "Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle" (1"The Tan Sheet" July 13, 2009), we should not have stated that a citizen petition relating to stevia-based sweeteners in food products "is rendered irrelevant" by FDA's letters of no objection to marketers of stevia products. The letters state FDA's decision does not consider whether the products in question might violate Sec. 912 of FDAAA. "The Tan Sheet" regrets the misstatement
You may also be interested in...
Senate Puts FDA On Notice To Solve FDAAA Sec. 912 Puzzle
Senate appropriators say FDA must decide how it will implement a provision of the FDA Amendments Act of 2007 that could substantially stifle innovation in the dietary supplement industry
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.